Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2008

View Archived Issues

Bristol-Myers Squibb presents overview of second quarter

FDA has granted orphan drug designation to Ikaria's inhaled carbon monoxide for DGF

[11C]MePPEP, a novel PET ligand for CB1 shows good uptake and slow washout in human brain

Preclinical activity supports development of antiinfective acne treatment HB-1345

Preclinical positive results for serotonin receptor antagonists in learning and memory processing

Further phase II data on dimebon in Alzheimer's disease presented

New preclinical, phase I data on CTS-21166 made available

Senexis identifies promising beta-amyloid aggregation inhibitor

Novel anticancer agents described in recent patents

FDA allows Medarex's IND application to initiate phase I clinical trial of MDX-1105

Lorus reports positive results from two toxicology studies of LOR-2040 in bladder cancer

Diatos initiates recruitment into phase II clinical trials of DTS-201 in prostate and breast cancer

New agents for anxiety, psychosis, depression, etc. revealed in patent literature

Recent patents report discovery of novel antidiabetic agents

BioAlliance and APR sign European licensing agreement for ondansetron RapidFilm

Hollis-Eden initiates phase I/II clinical trial of Triolex and methotrexate in RA

Clinical Data acquires Adenosine Therapeutics

Novartis completes recruitment into phase III study of salmon calcitonin

Generex is granted approval to initiate trial of Generex Oral-lyn in IGT

Meda submits registration application to the FDA for extra strength azelastine nasal spray

Cancidas approved for use in pediatric patients

Heplisav phase III study meets primary endpoint

Intercell completes acquisition of Iomai

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...